GE HealthCare Technologies Inc.

GE HealthCare Technologies Inc. is a global leader in medical imaging, ultrasound, and pharmaceutical diagnostics, headquartered in Chicago, Illinois. Spun off from General Electric in 2023, the company has established itself as an independent force in medtech with US$20.6 billion in 2025 revenue, approximately 54,000 employees, and operations spanning 160+ countries.

Core Business

GE HealthCare operates through four reportable segments — Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics (PDx). The Imaging segment, accounting for the largest share of revenue, encompasses MRI, CT, molecular imaging, X-ray, and mammography systems with a significant installed base exceeding 5 million units globally. In FY2025, the Imaging division generated US$9.24 billion in revenue, supported by flagship platforms such as the SIGNA MRI family and Revolution CT series. The PDx segment represents a unique competitive advantage as one of the world's few large-scale manufacturers of iodinated contrast media, with a dedicated manufacturing campus in Cork, Ireland recently expanded with a US$138 million investment, and grew an exceptional 15.6% year-on-year. The company's AI-enabled portfolio includes over 80 FDA-cleared AI devices, more than any other medical technology company, spanning automated image reconstruction, workflow automation, and clinical decision support across imaging modalities.

Global Presence

The company maintains 44 manufacturing facilities, 32 of them owned, across 17 countries spanning the United States, Europe, and Asia, with flagship sites in Waukesha (Wisconsin), Cork (Ireland), Hino (Japan), and Beijing (China). Key European operations include the Buc facility near Paris, a center of excellence for high-end X-ray and interventional imaging, and Helsinki, Finland, which hosts patient monitoring manufacturing. In India, GE HealthCare invested US$50 million in its largest technology innovation center in Bengaluru, supporting software and AI development. With approximately 54,000 employees worldwide, the company serves customers in 160+ countries. The United States remains the largest market, followed by EMEA and China, with emerging markets in Southeast Asia and Latin America contributing accelerating growth. The company's global service network of thousands of field engineers provides installation, preventive maintenance, and remote monitoring for installed imaging and monitoring systems.

Key Strengths

GE HealthCare's competitive advantages are anchored in its unmatched installed base of over 5 million imaging and monitoring units, generating substantial recurring service and upgrade revenue. The company's leadership in AI-enabled imaging, with more than 80 FDA-cleared AI devices, positions it at the forefront of radiology's digital transformation, particularly through its Edison platform and AIR™ Recon DL deep-learning reconstruction. The Pharmaceutical Diagnostics franchise provides a defensible moat as one of only a few global manufacturers of iodinated contrast media and tracers, with the 15.6% PDx growth in FY2025 reflecting resilient demand for contrast-enhanced procedures. GE HealthCare's strong free cash flow generation — approximately US$1.7 billion in FY2025 — funds continued R&D investment and disciplined capital returns. The company also benefits from deep clinical relationships and brand trust built over more than a century of imaging innovation, from the first CT scanners to today's photon-counting and spectral CT platforms.

Challenges & Outlook

GE HealthCare faces several strategic challenges in the 2026-2027 horizon. China's healthcare procurement reforms and anti-corruption campaign have compressed demand for high-end imaging in its second-largest market, requiring the company to pivot toward service-led growth and localized product strategies. Intense competition from Siemens Healthineers, Philips, Canon Medical, and fast-rising Chinese challengers such as United Imaging pressures pricing across MRI and CT categories. Tariff and supply-chain realignment costs, driven by geopolitical tensions, add margin pressure. Looking forward, the company is investing in photon-counting CT technology (through its DeepHealth and Revolution platforms), AI-native workflows, and precision diagnostics that integrate imaging with molecular information. Management targets mid-single-digit organic growth and continued margin expansion through the "precision care" strategy, positioning GE HealthCare to defend its leadership while capturing the shift toward earlier, more accurate diagnosis.

VerityRank Score of 89/100